Aspirin Instead of Clopidogrel after Percutaneous Coronary Intervention in Atrial Fibrillation: More than just an Option

Key Points

• To evaluate the efficacy of aspirin versus clopidogrel as antiplatelet therapy in patients with atrial fibrillation after coronary intervention.
• Randomized trial design involving patients with atrial fibrillation
• Comparison of aspirin and clopidogrel efficacy post-percutaneous coronary intervention
• Assessment of outcomes related to antiplatelet therapy
• Aspirin shows a significant reduction in adverse cardiovascular events compared to clopidogrel (HR 0.75, 95% CI 0.60-0.94, P=0.018)
• Patients on aspirin experienced fewer bleeding complications compared to clopidogrel (P=0.003)
• Overall survival rates improved in the aspirin group by 15% over clopidogrel.